- Home
- CURV vs ABVX Comparison
CURV vs ABVX Comparison
Compare CURV & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURV
- ABVX
- Stock Information
- Founded
- CURV 2001
- ABVX 2013
- Country
- CURV United States
- ABVX France
- Employees
- CURV N/A
- ABVX N/A
- Industry
- CURV Clothing/Shoe/Accessory Stores
- ABVX
- Sector
- CURV Consumer Discretionary
- ABVX
- Exchange
- CURV Nasdaq
- ABVX Nasdaq
- Market Cap
- CURV 551.2M
- ABVX 451.5M
- IPO Year
- CURV 2021
- ABVX N/A
- Fundamental
- Price
- CURV $5.23
- ABVX $7.74
- Analyst Decision
- CURV Hold
- ABVX Buy
- Analyst Count
- CURV 4
- ABVX 4
- Target Price
- CURV $5.00
- ABVX $31.50
- AVG Volume (30 Days)
- CURV 216.1K
- ABVX 221.8K
- Earning Date
- CURV 06-05-2025
- ABVX 03-24-2025
- Dividend Yield
- CURV N/A
- ABVX N/A
- EPS Growth
- CURV 36.36
- ABVX N/A
- EPS
- CURV 0.15
- ABVX N/A
- Revenue
- CURV $1,103,737,000.00
- ABVX $11,456,982.00
- Revenue This Year
- CURV $0.48
- ABVX $284.20
- Revenue Next Year
- CURV N/A
- ABVX N/A
- P/E Ratio
- CURV $34.77
- ABVX N/A
- Revenue Growth
- CURV N/A
- ABVX 135.94
- 52 Week Low
- CURV $2.18
- ABVX $4.77
- 52 Week High
- CURV $9.14
- ABVX $14.71
- Technical
- Relative Strength Index (RSI)
- CURV 43.83
- ABVX 71.01
- Support Level
- CURV $5.03
- ABVX $5.59
- Resistance Level
- CURV $5.54
- ABVX $6.09
- Average True Range (ATR)
- CURV 0.27
- ABVX 0.40
- MACD
- CURV -0.04
- ABVX 0.13
- Stochastic Oscillator
- CURV 27.04
- ABVX 93.92
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.